Abstract 253: Pharmacological and Genetic Inhibition of Transient Receptor Potential Canonical 6 (TRPC6) as a Novel Treatment for Heart Failure and Duchenne Muscular Dystrophy (DMD) Pharmacological and Genetic Inhibition of Transient Receptor Potential Canonical 6 (TRPC6) as a Novel Treatment for Heart Failure and Duchenne Muscular Dystrophy (DMD)

Brian Leei Lin,Sumita Mishra,Grace K. Muller,Djahida Bedja,Guangshuo Zhu,Jinying Yang,Mark E. Anderson,Steve Pullen,David A. Kass

Abstract 253: Pharmacological and Genetic Inhibition of Transient Receptor Potential Canonical 6 (TRPC6) as a Novel Treatment for Heart Failure and Duchenne Muscular Dystrophy (DMD) Pharmacological and Genetic Inhibition of Transient Receptor Potential Canonical 6 (TRPC6) as a Novel Treatment for Heart Failure and Duchenne Muscular Dystrophy (DMD)

2019

Brian Leei Lin
Sumita Mishra
Grace K. Muller
Djahida Bedja
Guangshuo Zhu
Jinying Yang
Mark E. Anderson
Steve Pullen
David A. Kass

Intro: Duchenne muscular dystrophy (DMD) patients suffer from spinal deformities (scoliosis and kyphosis) and die prematurely in their thirties, mostly due to heart disease. DMD is caused by the la...

Keywords:

TRPC6
Cardiology
Duchenne muscular dystrophy
Bioinformatics
Diabetes mellitus
Transient receptor potential channel
Internal medicine
Biology
Heart failure

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations